Observational studyFuture oncology (London, England)2025
Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort.
Talha Munir et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.